Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) just unveiled an update.
HUTCHMED highlighted the publication in The Lancet of Phase III SACHI trial results, which show that combining its MET inhibitor savolitinib (ORPATHYS®) with AstraZeneca’s osimertinib (TAGRISSO®) significantly improves progression-free survival and response rates versus chemotherapy in patients with advanced EGFR-mutated non-small cell lung cancer who develop MET amplification after prior EGFR-TKI treatment. The data underpin the June 2025 regulatory approval in China for the all-oral savolitinib–osimertinib regimen, reinforcing HUTCHMED’s position in precision oncology and expanding treatment options for a difficult-to-treat subset of lung cancer patients, with a tolerable safety profile and potential to further entrench the company’s role in MET-targeted therapy alongside AstraZeneca.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$23.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies, including the MET tyrosine kinase inhibitor savolitinib (marketed in China as ORPATHYS®), for patients with advanced solid tumors such as non-small cell lung cancer. It operates in partnership with AstraZeneca, which co-develops and commercializes savolitinib in China and is targeting patient populations with defined genetic drivers, including EGFR mutations and MET aberrations.
Average Trading Volume: 5,055,888
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$20.27B
For an in-depth examination of 0013 stock, go to TipRanks’ Overview page.